Wall Street is positive on Hepion Pharmaceuticals Inc (HEPA). On average, analysts give Hepion Pharmaceuticals Inc a Strong Buy rating. The average price target is $10, which means analysts expect the stock to increase by 392.61% over the next twelve months.
That average ranking earns Hepion Pharmaceuticals Inc an Analyst Rating of 78, which is better than 78% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve.
InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.
What's Happening With Hepion Pharmaceuticals Inc Stock Today?
Hepion Pharmaceuticals Inc (HEPA) stock is trading at $2.03 as of 12:01 PM on Thursday, Feb 25, a decline of -$0.14, or -6.39% from the previous closing price of $2.17. The stock has traded between $2.02 and $2.13 so far today. Volume today is low. So far 4,702,273 shares have traded compared to average volume of 6,683,774 shares.
Click Here to get the full report on Hepion Pharmaceuticals Inc (HEPA) Stock.
